Cannabidiol (CBD) is one of the phytocannabinoids found in the cannabis plant. According to multiple scientific and medical sources, CBD has important medical benefits. Since 2013, the National Institutes of Health (PubMed) service has included over 1,100 studies on CBD in its index.
The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole). Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder. Alembic Pharmaceuticals Ltd., Hetero Labs Ltd., Teva Pharmaceuticals and Torrent Pharmaceuticals Ltd. have received FDA approval to market generic aripiprazole in multiple strengths and dosage forms.
Abilify (aripiprazole is an antipsychotic medication. It works by changing the actions of chemicals in the brain. Abilify is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar I disorder (manic depression). It is not known if aripiprazole is safe or effective in children younger than 13 with schizophrenia, or children younger than 10 with bipolar disorder. Abilify is also used together with other medicines to treat major depressive disorder in adults.